LillyDirect and ŌURA partner to link wearable data with obesity treatment
The deal ties sleep and activity tracking to a prescription platform, though it is not yet clear what the ring costs, when it starts, or who sees the data.
Eli Lilly's direct-to-consumer telehealth platform LillyDirect and the Finnish health technology company ŌURA have announced a collaboration that connects Oura Ring sleep and activity tracking to obesity treatment [1]. Under the agreement, LillyDirect customers will be able to receive a free sizing kit for the Oura Ring [1].
The companies describe the arrangement as a way to combine behavioral and pharmaceutical approaches to obesity care, rather than relying on medication alone [1]. ŌURA says more than half of its user base consider themselves overweight or obese, and that tens of thousands of those users log their use of obesity therapies such as GLP-1 receptor agonists in the company's app [1].
ŌURA's chief marketing officer, Ricky Bloomfield, said the growth of GLP-1 drugs in clinical care creates a chance to influence outcomes. "By integrating daily habits with real-time biometric insights, we can offer a more connected and personalised approach to support lasting results – not just in weight on the scale, but in how people feel and function every day," he said [1].
Jannifer Mazur, US senior vice president at LillyDirect, said the discussion around obesity care is no longer only about what patients need at the point of prescription, and now centers on "daily moments that shape long-term success" [1]. Earim Chaudry, chief medical officer of the online weight-loss clinic Voy, made a similar point at the 2026 HLTH Europe conference in Amsterdam, describing medications as "the start, not the destination" [1].
This is not ŌURA's first move into the category. The company previously launched GLP-1 Insights, a tool that gives patients on GLP-1 receptor agonists a data-based view of their progress on treatment [1]. Outside obesity, ŌURA has also integrated Dexcom's over-the-counter continuous glucose monitor, Stelo, into its offering, letting non-diabetic users track blood glucose [1]. Lilly, for its part, has worked with the UK government on access to digital platforms and community-based obesity support in Britain [1].
The announcement did not name which Lilly medicines the collaboration covers. It also did not say whether the Oura Ring itself will be free or discounted for LillyDirect customers, only that the sizing kit is free [1]. The cost of the ring, the cost of any subscription, the start date of the program, and any eligibility rules have not been disclosed [1].
Why it matters for patients
For people taking or considering GLP-1 medications, this is a business arrangement rather than a change in what the drugs do or in insurance coverage. Nothing in the announcement changes how semaglutide or tirzepatide products are prescribed or covered [1].
What it does signal is that the companies selling these prescriptions are increasingly building services around them, including wearables that collect sleep, activity and other daily data [1]. That raises practical questions the announcement leaves open: whether a patient's ring data would be visible to LillyDirect, to a prescribing clinician, or to neither, and what a patient would pay beyond the free sizing kit [1]. None of that has been disclosed [1].
Patients who already use an Oura Ring and take a GLP-1 drug are, in effect, already part of the data set ŌURA describes, since the company says tens of thousands of its users log obesity therapies in the app [1].
What happens next
The announcement sets no timetable. It is not yet known when the sizing kit offer begins, how long it will run, or whether the collaboration will expand beyond the sizing kit to include data sharing or other services [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.